1. Introduction {#s0005}
===============

*Streptococcus pneumoniae* is a leading infectious cause of global morbidity and mortality [@b0005] and a primary etiology of bacterial meningitis, along with *Neisseria meningitidis* and *Haemophilus influenzae* [@b0010]. In 2017, an estimated 445,000 cases of pneumococcal meningitis with 42,000 deaths occurred globally [@b0015]. In the meningitis belt of sub-Saharan Africa, pneumococcal meningitis has a distinct seasonality similar to that of meningococcal meningitis, high case fatality ratio (CFR), and predominance of serotype 1 disease in persons aged \>5 years [@b0020], [@b0025], [@b0030], [@b0035], [@b0040], [@b0045].

Burkina Faso is a West African country that is located entirely within the meningitis belt and experiences hyper-endemic rates of meningitis [@b0050]. After the successful introductions of the *H. influenzae* serotype b (Hib) vaccine in 2006 [@b0055] and the meningococcal serogroup A conjugate vaccine (MACV, MenAfriVac®) in 2010 [@b0060], [@b0065], *S. pneumoniae* became the predominant cause of the remaining bacterial meningitis burden in Burkina Faso. The government of Burkina Faso introduced 13-valent pneumococcal conjugate vaccine (PCV13) into the routine childhood immunization program in October 2013 using a schedule with 3 primary doses given at 8, 12, and 16 weeks of age without a booster or catch-up campaign. The WHO-UNICEF estimate of vaccination coverage with 3 doses of PCV13 in Burkina Faso was 91% for 2014--2017 [@b0070]. Burkina Faso is one of the few African countries to both successfully implement nationwide case-based meningitis surveillance and to also routinely serotype all pneumococcal meningitis specimens, in an effort to evaluate PCV13 impact [@b0045], [@b0075], [@b0080], [@b0085], [@b0090].

Before PCV13 introduction in Burkina Faso, the highest pneumococcal meningitis incidence and mortality occurred among children aged \< 1 year, and 71% of cases were due to PCV13 serotypes [@b0090]. In the first 4 years after nationwide PCV13 introduction, meningitis due to PCV13-serotypes declined substantially (62%), both among vaccinated age groups (children aged \< 1 year: 77% reduction) and among older age groups potentially benefitting from herd protection (persons aged ≥ 15 years: 64% reduction) [@b0075], [@b0080]. However, the decline in incidence was larger for PCV13 serotypes excluding serotype 1 (79% reduction) than for serotype 1 (52% reduction). These data suggested impact of PCV13, but that efforts to improve control of serotype 1, such as switching from a 3 + 0 schedule to a 2 + 1 schedule, may improve overall control of pneumococcal meningitis in this setting [@b0075], [@b0095].

Numerous countries in sub-Saharan Africa, including neighboring Ghana, struggle to control pneumococcal meningitis burden and outbreaks, even in the context of high coverage with pneumococcal conjugate vaccine (PCV) [@b0040], [@b0100], [@b0105], [@b0110], [@b0115], [@b0120], [@b0125]. Unlike for meningococcal meningitis, there is no formal epidemic definition or outbreak response guidelines for pneumococcal meningitis [@b0130]. These experiences prompted discussions about potential methods to prevent and respond to pneumococcal meningitis outbreaks in the meningitis belt [@b0135]. To help inform these discussions, we retrospectively examined Burkina Faso's case-based meningitis surveillance data to identify and describe pneumococcal meningitis clusters. These data help us understand pneumococcal meningitis epidemiologic dynamics that may be hidden within the predominant context of meningococcal meningitis in this region. We also examined the trajectories of identified clusters to assess whether vaccination or other response strategies could have potentially been used to decrease the spread or duration of the identified clusters.

2. Materials and methods {#s0010}
========================

2.1. National surveillance system {#s0015}
---------------------------------

Burkina Faso has collected high-quality case-based meningitis surveillance data nationwide since 2010 [@b0085], [@b0090]. Case-level demographic and clinical information, as well as cerebrospinal fluid (CSF) specimens, were collected from all suspected meningitis cases in all districts using WHO and MenAfriNet instruments [@b0140], [@b0145]; specimens were tested at 5 national reference laboratories. From 2011 to 2015, Burkina Faso had 63 districts total; following re-districting, this number changed to 70 districts in 2016 and 2017.

According to WHO case definitions [@b0150], a suspected meningitis case is sudden onset of fever ≥ 38.5 °C with neck stiffness, altered consciousness, or other meningeal signs (including flaccid neck, bulging fontanel, or convulsions in young children). A laboratory-confirmed pneumococcal meningitis case is a suspected case with *S. pneumoniae* isolated from CSF by culture or detected in CSF by real-time polymerase chain reaction (PCR) targeting the *lytA* gene or latex agglutination, using laboratory methods previously described [@b0090], [@b0155]. In the case of discrepant results for case confirmation, methods were considered confirmatory in the following order: PCR, culture, and latex agglutination. Serotyping of confirmed pneumococcal cases was performed using a multiplex real-time PCR approach targeting 37 serotypes; this method detects all 13 vaccine serotypes but is unable to differentiate some genetically similar serotypes (e.g., 6A/6B, 12F/12A/12B/44/46) [@b0160]. Not all pneumococci were serotyped, as some cases were only confirmed via latex agglutination, and some did not have a specimen or isolate available for serotyping or had an insufficient quantity available for serotyping.

2.2. Statistical methods {#s0020}
------------------------

We retrospectively analyzed pneumococcal meningitis cases diagnosed from January 1, 2011 to December 31, 2017. Cases in non-residents of Burkina Faso (n = 56) were excluded from the analyses. Pneumococcal meningitis cases were categorized as due to PCV13 serotypes (1, 3, 4, 5, 6A/6B, 7F/7A, 9 V/9A, 14, 18C/18F/18B/18A, 19A, 19F, or 23F), non-PCV13 serotypes, or non-typeable specimens [@b0090]. The numbers of suspected, pneumococcal, meningococcal, and *H. influenzae* meningitis cases reported per district per WHO epidemiologic week (i.e., a district-week) were calculated. Crude annual incidences (cases per 100,000 persons) were calculated using district-level population census estimates projected from the 2006 census. In 2017, Burkina Faso had a total population of 19,632,147 and an estimated birth cohort of 762,074 [@b0165]. The CFRs were calculated by dividing the number of reported deaths by the total number of cases.

For the purposes of this analysis, a cluster was defined as ≥ 5 confirmed pneumococcal meningitis cases reported in a district in one WHO epidemiologic week. For each identified cluster, we reviewed the case counts, incidence, serotypes, age distribution, and other detected pathogens for all suspected meningitis cases reported in that district during the year of the cluster. We described some key illustrative clusters. We also compared the weekly incidence of suspected cases to thresholds of ≥ 10, ≥ 5, or ≥ 3 cases per 100,000 population, to see whether any of these potential alert thresholds could have detected these pneumococcal meningitis clusters in "real time". We also compared the clusters to the 2016 WHO provisional pneumococcal meningitis outbreak definition, which includes 3 required elements: 1) a district or subdistrict with a weekly incidence of \>5 suspected cases per 100,000 population; 2) \>60% of confirmed meningitis cases caused by *S. pneumoniae*; and 3) \>10 confirmed cases of pneumococcal meningitis [@b0130].

2.3. Study approval {#s0025}
-------------------

This analysis was approved by Burkina Faso Ministry of Health ethical committee and was determined by the Centers for Disease Control and Prevention's (CDC) Human Research Protection Office to be public health non-research. As this analysis involved routinely-collected surveillance data, informed consent was not required. Surveillance data were anonymized to maintain patient privacy and confidentiality.

3. Results {#s0030}
==========

3.1. Pneumococcal meningitis surveillance data {#s0035}
----------------------------------------------

From 2011 to 2017, 23,705 suspected meningitis cases were reported in Burkina Faso ([Table 1](#t0005){ref-type="table"}). CSF was collected in almost all cases (98%), and 15,193 (64%) of CSF specimens were tested via latex, culture, or PCR. In total, 3498 (15%) suspected meningitis cases were laboratory-confirmed as *S. pneumoniae*. The majority (87%) of pneumococcal meningitis cases were confirmed using PCR, with or without another positive test (see Supplemental Table). In total, 2652 (76%) pneumococcal specimens were serotyped. Among these, 2156 (81%) had a serotype and 496 (19%) were non-typeable. The proportion of pneumococcal meningitis cases that were serotyped increased from 60% in 2011 to 86% in 2017. The CFR among all pneumococcal meningitis cases was 20%.Table 1Meningitis cases, Burkina Faso, 2011--2017.**Pre-PCV13 introductionPost-PCV13 introduction2011201220132014201520162017TotalN (%)N (%)N (%)N (%)N (%)N (%)N (%)N (%)**Suspected meningitis cases284164992829339929702659250823,705 CSF collected2766(97)6302(97)758(97)3331(98)2912(98)2603(98)2474(99)23,146(98) CSF tested[a](#tblfn1){ref-type="table-fn"}1718(60)2894(45)2011(71)2312(68)2229(75)2140(80)1889(75)15,193(64)Pneumococcal meningitis cases[b](#tblfn2){ref-type="table-fn"}6424624245025515203973498 Confirmed using PCR474(74)353(76)383(90)447(89)520(94)487(94)370(93)3034(87) Serotyped384(60)326(71)326(77)390(78)487(88)397(76)342(86)2652(76) PCV13 serotypes291(76)234(72)212(65)298(76)340(70)244(62)194(57)1813(68) Non-PCV13 serotypes30(8)49(15)62(19)53(14)47(10)59(15)43(13)343(13) Nontypeable specimens63(16)43(13)52(16)39(10)100(21)94(24)105(31)496(19) Reported deaths179(28)94(20)84(20)99(20)101(18)90(17)49(12)696(20)[^1][^2][^3][^4]

3.2. Pneumococcal meningitis cluster identification {#s0040}
---------------------------------------------------

Burkina Faso was comprised of 63 districts from 2011 to 2015 and 70 districts in 2016--2017, resulting in a total of 23,723 district-level epidemiologic weeks (i.e., district-weeks from 2011 to 2017). In 20 (0.08%) of these district-weeks, ≥5 confirmed pneumococcal meningitis cases were reported in a district in a single week, indicating a pneumococcal meningitis cluster. In 11 (55%) of these clusters, 5 pneumococcal meningitis cases were reported in that district-week; 7 (35%) of the clusters consisted of 6 pneumococcal meningitis cases; and 2 (10%) of the clusters had 7 pneumococcal meningitis cases ([Fig. 1](#f0005){ref-type="fig"}). No districts in Burkina Faso reported \>7 pneumococcal meningitis cases in a single week during 2011--2017.Fig. 1District-level epidemiologic weeks (i.e. district-weeks) with ≥ 5 pneumococcal meningitis cases reported in a district in one week, Burkina Faso, 2011--2017. Note: In 2012, epidemiologic weeks 14, 15, and 16 in the district of Koudougou made up 3/5 of the district-weeks with ≥ 5 pneumococcal meningitis cases. Similarly, in 2014, epidemiologic weeks 2, 3, and 4 in the district of Houndé made up all 3 of the district-weeks with ≥ 5 pneumococcal meningitis cases.

3.3. Pneumococcal meningitis cluster description {#s0045}
------------------------------------------------

Most of the identified clusters (15/20; 75%) occurred prior to PCV13 introduction in October 2013 ([Fig. 1](#f0005){ref-type="fig"}). Nearly half of clusters (9/20; 45%) were reported in 2011; these clusters varied geographically and temporally, occurring in 8 different districts and in epidemiologic weeks 3 to 11 ([Table 2](#t0010){ref-type="table"}). In 2011, only 1 district (Kaya) reported ≥ 5 pneumococcal meningitis cases in 2 different though consecutive weeks (weeks 10 and 11). In 2012, three of the districts-weeks with ≥ 5 reported pneumococcal meningitis cases were in fact part of a larger cluster that occurred in the same district (Koudougou) in consecutive weeks (weeks 14, 15, and 16). Similarly, in 2014, all three of the district-weeks with ≥ 5 cases occurred in Houndé in weeks 2, 3, and 5 (also, 3 cases occurred in week 4). No clusters were detected in 2015 or 2016. In 2017, 2 districts (Kaya and Titao) had clusters of 5 cases each.Table 2Retrospectively identified pneumococcal meningitis clusters defined as ≥ 5 confirmed pneumococcal meningitis cases reported in a district in one week, Burkina Faso, 2011--2017.**YearDistrictEpidemiologic WeekNo. suspected casesSuspected case incidence (per 100,000)No. pneumococcal meningitis cases**[a](#tblfn3){ref-type="table-fn"}**No. lab-confirmed cases**[b](#tblfn4){ref-type="table-fn"}**Proportion of all lab-confirmed cases**[b](#tblfn4){ref-type="table-fn"}**that week due to *S. pneumoniae***2011Dafra6124.466100%2011Houndé893.46786%2011Karangasso Vigué81011.066100%2011Kaya1091.76786%2011Kaya1171.455100%2011Ouahigouya9102.366100%2011Pama81010.65771%2011Saponé366.455100%2011Tenkodogo784.07888%2012Dori1072.35683%2012Koudougou14122.76786%2012Koudougou1592.177100%2012Koudougou16122.855100%2012Ouahigouya15429.255100%2013Boromo1062.355100%2014Houndé2299.855100%2014Houndé3196.45683%2014Houndé5113.766100%2017Kaya7112.85771%2017Titao452.655100%[^5][^6]

Of the 111 pneumococcal meningitis cases comprising the 20 clusters, 69 (62%) were serotyped. Of those, 51 (74%) were serotype 1, 10% were PCV13 serotypes besides serotype 1, 9% were non-PCV13 serotypes, and 7% were nontypeable ([Fig. 2](#f0010){ref-type="fig"}). Serotype 1 was over-represented among cluster-associated cases, as 49% of all serotyped pneumococcal meningitis cases occurring in Burkina Faso in 2011--2017 were serotype 1 (*P* \< 0.01). However, the serotype 1 cases often occurred among a background of meningitis cases due to other pneumococcal serotypes, meningococcal serogroups, and *H. influenzae* (see Supplemental Material for detailed descriptions of each cluster). During the weeks when a district reported ≥ 5 pneumococcal meningitis cases, the proportion of laboratory-confirmed meningitis cases in that district that were due to pneumococcus ranged from 71% to 100% (median: 100%, [Table 1](#t0005){ref-type="table"}).Fig. 2Serotype distribution of pneumococcal meningitis cases occurring in districts with ≥ 5 pneumococcal meningitis cases reported in one week, Burkina Faso, 2011--2017.

The age distribution of cluster-associated cases (median: 9 years, interquartile range \[IQR\]: 4--13 years) did not significantly differ from non-cluster-associated pneumococcal meningitis cases (median: 10 years, IQR: 4--17 years; Wilcoxon *P* = 0.16).

3.4. Example clusters {#s0050}
---------------------

### 3.4.1. Koudougou 2012 {#s0055}

In 2012, the district of Koudougou (population 433,545) reported ≥ 5 pneumococcal meningitis cases in each of 3 consecutive weeks (weeks 14, 15, and 16; see Supplemental Material). During these 3 weeks, 33 suspected meningitis cases were reported; 19 were laboratory-confirmed (18 *S. pneumoniae*, 1 *H. influenzae*). The pneumococcal cases were reported from 14 different villages; 6/18 cases were serotyped, and all were serotype 1. Following this 3-week-long cluster, 1 pneumococcal meningitis case was reported in week 17 and none were reported during the next 5 weeks. The highest suspected case incidence occurred during weeks 14 and 16 (2.8 per 100,000).

### 3.4.2. Houndé 2014 {#s0060}

In 2014, the district of Houndé (population 294,865) reported ≥ 5 pneumococcal meningitis cases in 3 nearly consecutive weeks (weeks 2, 3, and 5; 3 cases were reported in week 4; see Supplemental Material for more detail). During weeks 2--5, 72 suspected meningitis cases were reported; 21 were laboratory-confirmed (19 *S. pneumoniae*, 2 *N. meningitidis*). Most pneumococcal cases were reported from 4 villages. In total, 14/19 cases were serotyped: 11 (79%) were serotype 1, 2 were serotype 5, and 1 was serotype 12F/12A/12B/44/46. Following this 4-week-long cluster, 11 pneumococcal meningitis cases due to 6 different serotypes were reported during the next 8 weeks. The highest suspected case incidence occurred during week 2 (9.8 per 100,000).

### 3.4.3. Comparison against potential alert thresholds and 2016 WHO provisional pneumococcal meningitis outbreak definition {#s0065}

For each of the 20 clusters, we compared the incidence of suspected cases to thresholds of ≥ 10, ≥ 5, or ≥ 3 cases per 100,000, to see whether any of these potential alert thresholds could have detected these pneumococcal meningitis clusters in "real time". Two of the 20 clusters had a suspected case incidence of ≥ 10 cases per 100,000: Karangasso Vigué and Pama, both in 2011 ([Table 2](#t0010){ref-type="table"}). Six of the clusters had a suspected case incidence of ≥ 5 cases per 100,000, and 10 had an incidence of ≥ 3 cases per 100,000.

None of the 20 clusters met the 2016 WHO provisional pneumococcal meningitis outbreak definition. While 6 clusters had a weekly incidence of \>5 suspected cases per 100,000 and all 20 clusters had \>60% of confirmed meningitis cases due to *S. pneumoniae*, none of the clusters had \>10 confirmed cases of pneumococcal meningitis in a single week.

4. Discussion {#s0070}
=============

This retrospective analysis of meningitis surveillance data from Burkina Faso identified 20 pneumococcal meningitis clusters of ≥ 5 cases reported in a district in a single week. However, none of these clusters met the 2016 WHO provisional pneumococcal meningitis outbreak definition. Though the identified clusters often included a mixture of pneumococcal serotypes, serotype 1 caused the majority (74%) of cases. Additionally, as most clusters were of short duration, there were no clear cases where reactive vaccination with PCVs might have been useful.

Though currently in sub-Saharan Africa, PCVs are currently only used in the context of routine childhood immunization via the Expanded Programme on Immunization, the WHO has suggested that pneumococcal vaccines could be used in mass vaccination for children and adults in outbreaks of pneumococcal meningitis, in a similar way to that used in outbreaks of meningococcal meningitis [@b0130]. However, there are a number of challenges when considering the potential role of PCVs for reactive vaccination. First, the effectiveness of reactive vaccination in reducing further cases of pneumococcal meningitis is not known [@b0130]. Reactive vaccination of districts or sub-districts requires an immense mobilization effort, so a clear understanding of the benefits is a prerequisite. Second, unlike the vaccines stockpiled for meningococcal meningitis outbreak response, the WHO's International Coordinating Group (ICG) on Vaccine Provision [@b0170], [@b0175] does not have a stockpile of PCVs. Third, laboratory confirmation of *S. pneumoniae* and the corresponding serotypes is not done in real-time in Burkina Faso. Unlike for meningococcal meningitis, where initial latex agglutination testing can give public health authorities an idea of serogroup and where serogroup confirmation can sometimes be performed by regional laboratories, pneumococcal serotyping is often performed in batches at the national level and results are only available and linked to epidemiologic data after significant delay. Fourth, when reactive vaccination was used in response to recent meningococcal meningitis outbreaks in the meningitis belt, the median response time was over 5 weeks (median: 36 days; range: 10--64 days) [@b0180] and an additional 2 weeks are assumed to be needed for development of an immune response, for a total of approximately 7 weeks before a vaccination response may begin to affect the trajectory of an outbreak. Therefore, by the time the necessary epidemiologic and laboratory information is pieced together and reactive PCV vaccination could be mobilized, it would likely be too late to produce any public health impact.

The two largest identified clusters occurred in the districts of Koudougou in 2012 and Houndé in 2014. In Koudougou, 18 confirmed pneumococcal meningitis cases occurred over 3 weeks; all serotyped cases were serotype 1. However, the cases occurred in many different villages, the suspected case incidence never crossed any potential alert thresholds, and there was likely no time for reactive vaccination to potentially play a role in public health response, as the cluster ended after 3 weeks. In Houndé, 19 confirmed pneumococcal meningitis cases occurred over 4 weeks. The cases were mainly concentrated in 4 villages, and the district reached a suspected case incidence of 9.8 cases per 100,000 in the first week of the cluster. Though this incidence crossed the 2016 WHO provisional outbreak definition of \>5 suspected cases per 100,000, it did not cross the currently-used alert threshold of 10 suspected cases per 100,000. Additionally, the cases were due to a variety of serotypes, though most were covered by PCV13. In this instance, there also likely would not have been time to implement a reactive vaccination campaign, and it may not have been pursued anyway due to the variety of serotypes involved.

In the absence of reactive vaccination, few effective public health prevention or response measures are available to control pneumococcal meningitis outbreaks once they start. Antibiotic chemoprophylaxis for household contacts is not recommended during pneumococcal meningitis outbreaks, as household members are not considered at increased risk and antibiotic prophylaxis is not known to be effective [@b0130]. Fortunately, we found fewer pneumococcal meningitis clusters in Burkina Faso after the nationwide PCV13 program was implemented, suggesting that the current infant vaccination program is helpful for preventing clusters.

One potential prevention tool that has been discussed to further reduce pneumococcal meningitis is to strive for better control of all invasive pneumococcal infections by adding a booster dose to the infant vaccination series [@b0075], [@b0185]. The WHO currently recommends both PCV booster-containing schedules (2 primary doses and 1 booster dose at 9--12 months of age: 2 + 1) and non-booster-containing schedules (3 primary doses: 3 + 0) [@b0190]. Most Gavi-eligible countries and all African countries except South Africa and Mozambique use a 3 + 0 schedule, as WHO initially recommended the 3 + 0 schedule, with the 2 + 1 schedule being an acceptable alternative [@b0195]. Many countries also implemented the 3 + 0 schedule for logistical harmonization with other infant immunizations and to maximize vaccination coverage. However, more recent data indicate that the 2 + 1 PCV schedule induces higher antibody levels in the second year of life [@b0095], [@b0190]. A booster dose could also lead to a longer duration of protection and improved effectiveness against serotype 1 disease [@b0195], and may help prevent PCV13-serotype pneumococcal carriage among toddlers, who are likely the primary source of pneumococcal transmission in the community [@b0095], [@b0200], [@b0205], [@b0210]. Based on these data, Burkina Faso is considering changing from a 3 + 0 to a 2 + 1 schedule, which would involve removing one of the 3 primary doses (the middle dose, given at age 12 weeks) and adding a booster dose at the 9--12 month visit along with the first dose of measles-containing vaccine. An additional prevention strategy that could be considered is a catch-up campaign for older children, given that the median age of cases remained 8--11 years both pre- and post-PCV13 introduction.

This analysis was an exploratory review of retrospective data, to see if any lessons could be gleaned to guide conversations around prevention and response of pneumococcal meningitis outbreaks in the meningitis belt. Though it adds to the relatively limited literature base on this topic, there are limitations to this analysis. First, as with any surveillance system, there is a possibility that not all pneumococcal meningitis cases were detected, diagnosed, and reported. Additionally, though much effort has gone into the serotyping of pneumococcal meningitis in Burkina Faso and the proportion of specimens serotyped increased from 60% in 2011 to 86% in 2017, not all cases were serotyped. Furthermore, this analysis relied on pneumococcal meningitis surveillance data; a greater understanding of pneumococcal transmission dynamics would require data on other clinical presentations of invasive pneumococcal disease, non-invasive presentations, and nasopharyngeal carriage. While these elements have been a focus of recent work in Burkina Faso, they are not factored into this retrospective analysis. Another limitation is one previously mentioned by Coldiron et al [@b0215] regarding the 2016 WHO provisional pneumococcal meningitis outbreak definition [@b0130]: it is unclear whether the criterion of \>10 confirmed pneumococcal meningitis cases refers to a single week or overall during the outbreak. We assumed this criterion referred to a single week for the purposes of this analysis. While an alternative interpretation of the criteria of \>60% of confirmed meningitis cases caused by *S. pneumoniae* and \>10 confirmed cases of pneumococcal meningitis could be considered on a cumulative basis rather than a weekly basis, a challenge remains in defining the time frame for calculating these cumulative measures, especially in districts that may cross the weekly incidence threshold of \>5 suspected cases per 100,000 population in non-consecutive weeks, such as in Houndé in 2014. Additionally, an outbreak definition using weekly measures would be most useful to inform real-time outbreak response, including potential reactive vaccination. Finally, during our limited years of observation, we did not detect any pneumococcal meningitis outbreaks in Burkina Faso similar in size to those recently reported in Ghana [@b0040], [@b0125]. Therefore, this analysis is unable to help inform models of pneumococcal meningitis outbreaks in the meningitis belt [@b0135].

This analysis adds to the growing literature regarding pneumococcal meningitis in the context of PCV implementation in West Africa [@b0040], [@b0100], [@b0105], [@b0115], [@b0120], [@b0125], [@b0135], [@b0220], [@b0225], [@b0230], [@b0235], [@b0240], [@b0245], [@b0250], [@b0255], from a country with nationwide population-based surveillance data with routine pneumococcal serotyping [@b0075], [@b0080], [@b0090]. Following the successful introductions of Hib vaccine and MACV, the epidemiology of bacterial meningitis in the meningitis belt is changing and *S. pneumoniae* is increasingly recognized as causing a high proportion of remaining disease [@b0045]. Though we did not identify any large pneumococcal meningitis outbreaks with a weekly incidence of \>7 cases or duration \>4 weeks in Burkina Faso, we provide data on smaller pneumococcal meningitis clusters to help inform discussions regarding potential prevention and response measures for pneumococcal meningitis in the context of the meningitis belt. We also reaffirmed the predominance of serotype 1 in pneumococcal meningitis clusters and outbreaks [@b0040], [@b0215]. Though we did not retrospectively identify any clear cases where reactive vaccination with PCV could have played a role in outbreak response, continued robust meningitis surveillance [@b0145], real-time specimen tracking [@b0260], high levels of laboratory confirmation [@b0265] and pneumococcal serotyping in Burkina Faso will allow for monitoring and detection of any future pneumococcal meningitis clusters or outbreaks, as well as evaluation of a potential change from a 3 + 0 schedule to a 2 + 1 schedule and how that may impact pneumococcal meningitis dynamics in Burkina Faso.
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[^1]: Note: Some of the data presented in this table have been previously published [@b0075].

[^2]: Abbreviations: CSF, cerebrospinal fluid; PCR, polymerase chain reaction; PCV13, 13-valent pneumococcal conjugate vaccine.

[^3]: Tested by culture, PCR, or latex agglutination.

[^4]: *S. pneumoniae* isolated from CSF by culture or detected in CSF by PCR or latex agglutination.

[^5]: *S. pneumoniae* isolated from CSF by culture or detected in cerebrospinal fluid (CSF) by polymerase chain reaction (PCR) or latex agglutination.

[^6]: *S. pneumoniae*, *N. meningitidis*, or *H. influenzae* isolated from CSF by culture or detected in CSF by PCR or latex agglutination.
